ClinicalTrials.gg
Active, not recruitingNCT03075072Updated Sep 29, 2026Results posted

Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial

An interventional study of Whole brain radiation and Stereotactic radiation (SRS) in Brain Metastases, sponsored by Brigham and Women's Hospital. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Sep 29, 2026Results postedStudy documents posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
196
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,447 studies in Brain Neoplasms with a site in United States — 233 open to participants now, 355 under way, 18 of them phase 3. Brain Neoplasms · United States.

Enrollment
80th of 1,192
196 · median 30
Started
2017
with 63 others
No phase
226 of 1,447
64 open now
Primary completion
2024-11
later than 15 of 353 live
Registered
946th of 1,447
by date

Among the 1,447 studies in Brain Neoplasms with a site in United States, this one is the 80th largest by enrollment of the 1,192 interventional ones that give a count, is one of 64 that started in 2017, is one of 226 with no phase, reaches primary completion later than 15 of the 353 other live ones, and was the 946th registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

233 of the 1,447 studies in Brain Neoplasms with a site in United States are open now. Recruiting first, the newest first:

228 more — sign in →

All 233 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,447 studies in Brain Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This research study is studying two different types of radiation as treatment for brain metastases (tumors in the brain that spread from a cancer that originated elsewhere in the body)

Read the detailed description

This research study is a Phase III clinical trial. Phase III clinical trials examine the safety and effectiveness of a treatment, often comparing it to another known treatment. In this case, the investigators are specifically looking at differences between two forms of radiation treatment in terms of subsequent quality of life.

In this research study, the investigators are comparing stereotactic (focused, pinpoint) radiation (in which each tumor is narrowly targeted) against whole brain radiation (radiation targeting the entire brain) in the treatment of brain metastases. Currently whole brain radiation is the standard option for patients with 5-20 brain metastases. Stereotactic radiation is the standard option for patients with 1-4 brain metastases. Among patients with 1-4 brain metastases, recently published studies suggest that stereotactic radiation results in fewer neurologic side effects than whole brain radiation. It also yields better quality of life in this population. It remains unknown whether stereotactic radiation improves quality of life in patients with 5-20 brain metastases relative to whole brain radiation. In this study, the investigators seek to determine which of the two methods of study treatment results in a better subsequent quality of life for patients with 5-20 brain metastases.

03

Conditions studied

  • Brain Metastases

Keywords

  • Brain metastases
  • Brain metastasis
  • Lung cancer
  • Melanoma
  • Breast cancer
  • Kidney cancer
  • Renal cell carcinoma
  • Stereotactic radiation
  • Stereotactic radiosurgery
  • SRS
  • Stereotactic
  • Whole brain radiation
  • WBRT
  • Hippocampal avoidance
  • Hippocampal sparing
  • Hippocampal
  • Hippocampus
  • Radiation
  • Quality of Life
  • Neurocognitive
  • Neurocognition
  • Survival
  • Salvage
  • MDASI
  • Chemotherapy
  • Recurrence
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a proven solid with untreated (by radiation) intracranial lesions radiographically consistent with or proven to be . Patients who have undergone prior systemic therapy are eligible
  • Five-twenty intracranial lesions must be present on MRI of the brain
  • Age 18-80 years at diagnosis of brain metastases
  • performance status of at least 70

Exclusion criteria

Exclusion Criteria:

  • Participants who have undergone prior radiation for .
  • Patients who have undergone resection of one or more brain metastases but who have not yet started radiotherapy are eligible for the study
  • Participants who cannot undergo a brain MRI
  • Participants who cannot receive gadolinium (MRI contrast)
  • Participants with stage IV-V chronic kidney disease or end stage renal disease
  • Participants with widespread, definitive
  • Participants with small cell lung cancer, lymphoma, or myeloma
  • Participants with a maximum tumor diameter exceeding 5 cm (if not resected)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
196 participants (actual)

Study arms

  • Active comparator
    Whole Brain Radiation

    * MRI will be performed prior to radiation is administered * A hippocampal sparing approach will be used when possible * Dose will be 30 Gy in 10 fractions

    Radiation: Whole brain radiation

  • Experimental
    Stereotactic Radiation (SRS)

    * MRI will be performed prior to radiation is administered * Radiation will be given in 1-5 fractions (dose depends on the size of the tumor that will be treated)

    Radiation: Stereotactic radiation (SRS)

Interventions

  • RadiationWhole brain radiation

    Treatment of the whole brain with radiation. When possible the hippocampus will be spared from radiation.

  • RadiationStereotactic radiation (SRS)

    Focused radiation to each individual brain metastasis without treatment of the remainder of the brain.

06

What researchers measure

Primary outcomes

  1. Change in MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT) Score

    Questionnaire - MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT). Results reflect patient-reported symptoms. Here they are presented as a mean change: the difference in the weighted mean of symptom severity and interference scores at baseline versus at 6 months. The difference between these scores is the mean change reported below. The MD Anderson Symptom Inventory has a scale of 0-10, 0 being not present and 10 being as bad as the patient could imagine. The calculated score change has a range of -10 to 10; -10 being the best. Change in score is calculated as the composite weighted means of symptom severity and interference at 6 months minus the composite weighted means of symptom severity and interference at baseline.

    Time frame: Baseline and 6 months post-Baseline

Secondary outcomes

  1. Overall Survival

    Clinical Parameter. Here we report the number of patients analyzed for the outcome as well as the number of deaths that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.

    Time frame: Through study completion, an average of 1 year

  2. 12 Month Cumulative Incidence of Neurologic Death

    Clinical parameter to be assessed via review of study visits and medical records indicating cause of death (neurologic versus systemic). Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.

    Time frame: Through study completion, an average of 1 year

  3. 12 Month Cumulative Incidence of New Brain Metastases

    Radiographic assessment of first appearance of new brain metastases. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.

    Time frame: Through study completion, an average of 1 year

  4. 12 Month Cumulative Incidence of Local Recurrence of Treated Brain Tumor(s)

    Radiographic assessment of first local recurrence in the 5-20 brain metastases that were initially treated with radiation. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.

    Time frame: Through study completion, an average of 1 year

  5. 12 Month Cumulative Incidence of Progressive Intracranial Disease

    Radiographic assessment of first instance of progressive intracranial disease. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.

    Time frame: Through study completion, an average of 1 year

  6. 12 Month Cumulative Incidence of Radiographic Radiation Necrosis

    Radiographic assessment of first appearance of radiation necrosis. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.

    Time frame: Through study completion, an average of 1 year

  7. 12 Month Cumulative Incidence of Leptomeningeal Disease

    Radiographic assessment of first appearance of leptomeningeal disease. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.

    Time frame: Through study completion, an average of 1 year

  8. 12 Month Cumulative Incidence of Dexamethasone Initiation

    Assessing time to dexamethasone initiation in patients who were not taking steroids at enrollment. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.

    Time frame: Through study completion, an average of 1 year

  9. 12 Month Cumulative Incidence of Development of Seizures

    Clinical assessment of first post-treatment seizure as assessed during routine study visits and via medical record review. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.

    Time frame: Through study completion, an average of 1 year

  10. 12 Month Cumulative Incidence of Salvage Stereotactic Radiation

    Clinical assessment of first use of salvage stereotactic radiation. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.

    Time frame: Through study completion, an average of 1 year

  11. 12 Month Cumulative Incidence of Salvage Whole Brain Radiation

    Clinical assessment of first use of salvage whole brain radiation with or without hippocampal avoidance. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.

    Time frame: Through study completion, an average of 1 year

  12. 12 Month Cumulative Incidence of Salvage Neurosurgical Resection

    Clinical assessment of first use of neurosurgical resection as salvage therapy. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.

    Time frame: Through study completion, an average of 1 year

  13. Mean Barthel Index Score at Baseline

    Barthel Index ranges from 0 to 100 with higher scores indicating greater functional independence. A greater difference between the groups indicates greater functional independence in the stereotactic arm. Here we report the mean Barthel Index score at baseline for both arms.

    Time frame: Baseline

  14. Change in Barthel Index Score at 4-months and 12-months Post-baseline

    Barthel Index ranges from 0 to 100 with higher scores indicating greater functional independence. A greater difference between the groups indicates greater functional independence in the stereotactic arm. Here we report the mean difference (95% Confidence Interval) at each timepoint.

    Time frame: 4 Months and 12 months

  15. Karnofsky Performance Status

    The Karnofsky Performance Status (KPS) is a tool designed to assess a cancer patient's functional status. Scores range from 0 to 100 with higher scores indicating better function. Scores 90-100 indicate that the patient is independent and can perform daily activities with little to no effort. A score of 80 indicates that the patient can conduct their normal activities with some effort. A score of 70 indicates that a patient can care for themself but cannot carry on normal activities independently. Here we report the least squares mean Karnofsky Performance Score for each arm based on the Karnofsky Performance Status Scale at each timepoint from Baseline to 12 Months post-baseline.

    Time frame: Baseline to 12 Months

  16. Hopkins Verbal Learning Test-Revised Total Recall Z-Score at Baseline

    Here we report the mean Hopkins Verbal Learning Test-Revised Total Recall (HVLT-R Total Recall) z-score in each arm at baseline. The HVLT-R Total Recall test measures rote verbal learning across 3 trials administered in one sitting. Scores were transformed into z scores. Z scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The Z-Score central value is 0 and represents the population mean. Larger positive z scores indicate better neurocognitive function.

    Time frame: Baseline

  17. Change in Hopkins Verbal Learning Test-Revised Total Recall Mean Z-Score at 4-Months and 12-Months Post-baseline

    Here we report the mean Hopkins Verbal Learning Test-Revised Total Recall (HVLT-R Total Recall) z-score in each arm at the given timepoint. The HVLT-R Total Recall test measures rote verbal learning across 3 trials administered in one sitting. Scores were transformed into z scores. Z scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The Z-Score central value is 0 and represents the population mean. Larger positive z scores indicate better neurocognitive function.

    Time frame: 4 Months and 12 Months

  18. Hopkins Verbal Learning Test-Revised Delayed Recall Z-Score at Baseline

    Here we report the mean Hopkins Verbal Learning Test-Revised Delayed Recall Z score at baseline. This test measures delayed memory function. Scores were transformed into z scores. Z scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The Z score central value is 0 and represents the population mean. Larger positive z scores indicate better neurocognitive function.

    Time frame: Baseline

  19. Change in Hopkins Verbal Learning Test-Revised Delayed Recall Z Scores at 4 Months and 12 Months

    Here we report the mean Hopkins Verbal Learning Test-Revised Delayed Recall Z score at the given timepoint. This test measures delayed memory function. Scores were transformed into z scores. Z scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The Z score central value is 0 and represents the population mean. Larger positive z scores indicate better neurocognitive function.

    Time frame: 4 Months and 12 months post-baseline

  20. Hopkins Verbal Learning Test-Revised Recognition Z Score at Baseline

    Here we report the mean Hopkins Verbal Learning Test-Revised Recognition z scores in each arm at baseline. The Hopkins Verbal Learning Test - Revised Recognition measures memory storage and recognition. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the populaion mean. Larger, positive z scores indicate better neurocognitive function. Here we report the mean z score in each arm at baseline.

    Time frame: Baseline

  21. Change in Hopkins Verbal Learning Test-Revised Recognition Z-score at 4 Months and 12 Months

    Here we report the mean Hopkins Verbal Learning Test-Revised Recognition z scores in each arm at the given timepoint. The Hopkins Verbal Learning Test - Revised Recognition measures memory storage and recognition. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the populaion mean. Larger, positive z scores indicate better neurocognitive function. Here we report the mean z score in each arm at the given timepoint.

    Time frame: 4 Months and 12 Months post baseline

  22. Trail Making Test A, Z Score at Baseline

    Here we report the mean Trail Making Test A z score in each arm at baseline. The Trail Making Test A measures visuomotor processing speed. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the population mean. Larger, positive z scores inicate better visuomotor processing speed.

    Time frame: Baseline

  23. Change in Trail Making Test A Z-Score From Baseline at 4 Months and 12 Months

    Here we report the mean Trail Making Test A z score in each arm at the given timepoint. The Trail Making Test A measures visuomotor processing speed. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the population mean. Larger, positive z scores inicate better visuomotor processing speed.

    Time frame: at 4 Months and 12 Months

  24. Trail Making Test B Z Score at Baseline

    Here we report the mean Trail Making Test B z score in each arm at baseline. The Trail Making Test B measures visuomotor processing speed. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the population mean. Larger, positive z scores inicate better visuomotor processing speed.

    Time frame: Baseline

  25. Trail Making Test B Z Score at 4 Months and 12 Months Post-baseline

    Here we report the mean Trail Making Test B z score in each arm at the given timepoint. The Trail Making Test B measures visuomotor processing speed. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the population mean. Larger, positive z scores inicate better visuomotor processing speed.

    Time frame: 4 Months and 12 months post-baseline

  26. Controlled Oral Word Test Z Score at Baseline

    Here we report the mean controlled oral word test z score in each arm at baseline. The controlled oral word test (COWAT) measures verbal fluency. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the population mean. A larger positive z score indicates better performance.

    Time frame: Baseline

  27. Change in Controlled Oral Word Test Z Score at 4 Months and 12 Months Post Baseline

    Here we report the change in mean controlled oral word test z score in each arm at the given timepoints from baseline. The controlled oral word test (COWAT) measures verbal fluency. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the population mean. A larger positive z score indicates better performance.

    Time frame: 4 Months and 12 months post baseline

  28. Mini-Mental State Examination Mean at Baseline

    Here we report the Mini-Mental State Examination mean in each arm at baseline. The Mini-Mental State Examination measures global cognition on a scale from 0 to 30. Higher scores indicate better perfromance.

    Time frame: Baseline

  29. Change in Mini-Mental State Examination Score at 4 Months and 12 Months Post Baseline

    Here we report the change in the mean Mini-Mental State Examination z score in each arm at the given timepoints. The Mini-Mental State Examination Scores measures global cognition on a scale from 0 to 30. Test scores were transformed into z scores Larger positive scores indicate better performance. Z scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The Z-Score central value is 0 and represents the population mean. Larger, positive differences indicate better global cognition.

    Time frame: 4 Months and 12 months post baseline

  30. Medical Outcomes Study Cognitive Functioning Scale-Revised Normative Score at Baseline

    Scores global cognition on a scale from 0 to 100. Higher scores indicate better cognitive function. Scores were transformed into normative scores ranging from 7.51 to 58.61. Larger scores indicate better function.

    Time frame: Baseline

  31. Change in Medical Outcomes Study Cognitive Functioning Scale-Revised Normative Scores at 4 Months and 12 Months Post Baseline

    Scores global cognition on a scale from 0 to 100. Higher scores indicate better cognitive function. Scores were transformed into normative scores ranging from 7.51 to 58.61. Larger positive differences indicate better function.

    Time frame: 4 Months and 12 months post baseline

07

Results

Posted Sep 29, 2026
Limitations and caveats
Per manuscript

Participant flow

The study was conducted by Brigham and Women's Hospital/ Dana-Farber Cancer Institute (Boston, MA) and took place at three additional cancer centers: Rhode Island Hospital/Brown University Health (Providence, RI), Milford Regional Medical Center (Milford, MA), and South Shore Health (Weymouth, MA). Patients were enrolled on study between April 2017 and May 2024.

Participant flow — Overall Study
MilestoneHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
Started9898
Completed8696
Not completed122

Outcome measures

PrimaryChange in MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT) Score

Questionnaire - MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT). Results reflect patient-reported symptoms. Here they are presented as a mean change: the difference in the weighted mean of symptom severity and interference scores at baseline versus at 6 months. The difference between these scores is the mean change reported below. The MD Anderson Symptom Inventory has a scale of 0-10, 0 being not present and 10 being as bad as the patient could imagine. The calculated score change has a range of -10 to 10; -10 being the best. Change in score is calculated as the composite weighted means of symptom severity and interference at 6 months minus the composite weighted means of symptom severity and interference at baseline.

Time frame:
Baseline and 6 months post-Baseline
Reported as:
Mean · Scores on a Scale
Change in MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT) Score
Scores on a ScaleHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
Change in MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT) Score0.7 ± 2.0-0.3 ± 1.4
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · Weighted T-test · p = <0.001 · Mean difference (net): -1.06 · 95% CI -1.54 to -0.58Weights based on number of baseline scores
SecondaryOverall Survival

Clinical Parameter. Here we report the number of patients analyzed for the outcome as well as the number of deaths that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.

Time frame:
Through study completion, an average of 1 year
Reported as:
Number · Percent of participants
Overall Survival
Percent of participantsHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
Overall Survival42.8 (32.7 to 52.6)41.1 (31.3 to 50.7)
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · Stratified log-rank test · p = 0.30
Secondary12 Month Cumulative Incidence of Neurologic Death

Clinical parameter to be assessed via review of study visits and medical records indicating cause of death (neurologic versus systemic). Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.

Time frame:
Through study completion, an average of 1 year
Reported as:
Number · Percent of participants
12 Month Cumulative Incidence of Neurologic Death
Percent of participantsHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
12 Month Cumulative Incidence of Neurologic Death8.5 (3.9 to 15.3)9.4 (4.6 to 16.3)
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · Stratified Fine and Gray Test · p = 0.35
Secondary12 Month Cumulative Incidence of New Brain Metastases

Radiographic assessment of first appearance of new brain metastases. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.

Time frame:
Through study completion, an average of 1 year
Reported as:
Number · percent of participants
12 Month Cumulative Incidence of New Brain Metastases
percent of participantsHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
12 Month Cumulative Incidence of New Brain Metastases24.2 (16.1 to 33.3)45.4 (35.2 to 55.0)
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · Stratified Fine and Gray Test · p = 0.003
Secondary12 Month Cumulative Incidence of Local Recurrence of Treated Brain Tumor(s)

Radiographic assessment of first local recurrence in the 5-20 brain metastases that were initially treated with radiation. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.

Time frame:
Through study completion, an average of 1 year
Reported as:
Number · percent of participants
12 Month Cumulative Incidence of Local Recurrence of Treated Brain Tumor(s)
percent of participantsHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
12 Month Cumulative Incidence of Local Recurrence of Treated Brain Tumor(s)39.5 (29.5 to 49.3)3.2 (0.8 to 8.3)
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · Gray's test · p = <0.001
Secondary12 Month Cumulative Incidence of Progressive Intracranial Disease

Radiographic assessment of first instance of progressive intracranial disease. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.

Time frame:
Through study completion, an average of 1 year
Reported as:
Number · percent of participants
12 Month Cumulative Incidence of Progressive Intracranial Disease
percent of participantsHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
12 Month Cumulative Incidence of Progressive Intracranial Disease39.4 (29.4 to 49.2)46.4 (36.2 to 56.0)
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · Gray's test · p = 0.15
Secondary12 Month Cumulative Incidence of Radiographic Radiation Necrosis

Radiographic assessment of first appearance of radiation necrosis. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.

Time frame:
Through study completion, an average of 1 year
Reported as:
Number · percent of participants
12 Month Cumulative Incidence of Radiographic Radiation Necrosis
percent of participantsHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
12 Month Cumulative Incidence of Radiographic Radiation Necrosis1.1 (0.1 to 5.3)14.8 (8.5 to 22.8)
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · Gray's test · p = 0.001
Secondary12 Month Cumulative Incidence of Leptomeningeal Disease

Radiographic assessment of first appearance of leptomeningeal disease. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.

Time frame:
Through study completion, an average of 1 year
Reported as:
Number · percent of participants
12 Month Cumulative Incidence of Leptomeningeal Disease
percent of participantsHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
12 Month Cumulative Incidence of Leptomeningeal Disease3.2 (0.8 to 8.3)8.3 (3.8 to 14.9)
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · Stratified Fine and Gray Test · p = 0.12
Secondary12 Month Cumulative Incidence of Dexamethasone Initiation

Assessing time to dexamethasone initiation in patients who were not taking steroids at enrollment. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.

Time frame:
Through study completion, an average of 1 year
Reported as:
Number · percent of participants
12 Month Cumulative Incidence of Dexamethasone Initiation
percent of participantsHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
12 Month Cumulative Incidence of Dexamethasone Initiation72.2 (55.7 to 83.4)52.2 (36.7 to 65.6)
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · Gray's test · p = 0.03
Secondary12 Month Cumulative Incidence of Development of Seizures

Clinical assessment of first post-treatment seizure as assessed during routine study visits and via medical record review. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.

Time frame:
Through study completion, an average of 1 year
Reported as:
Number · percent of participants
12 Month Cumulative Incidence of Development of Seizures
percent of participantsHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
12 Month Cumulative Incidence of Development of Seizures15.8 (9.3 to 24.0)11.4 (6.0 to 18.6)
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · Stratified Fine and Gray Test · p = 0.44
Secondary12 Month Cumulative Incidence of Salvage Stereotactic Radiation

Clinical assessment of first use of salvage stereotactic radiation. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.

Time frame:
Through study completion, an average of 1 year
Reported as:
Number · percent of participants
12 Month Cumulative Incidence of Salvage Stereotactic Radiation
percent of participantsHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
12 Month Cumulative Incidence of Salvage Stereotactic Radiation22.7 (14.7 to 31.7)15.5 (9.1 to 23.5)
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · Stratified Fine and Gray Test · p = .20
Secondary12 Month Cumulative Incidence of Salvage Whole Brain Radiation

Clinical assessment of first use of salvage whole brain radiation with or without hippocampal avoidance. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.

Time frame:
Through study completion, an average of 1 year
Reported as:
Number · percent of participants
12 Month Cumulative Incidence of Salvage Whole Brain Radiation
percent of participantsHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
12 Month Cumulative Incidence of Salvage Whole Brain Radiation1.0 (0.1 to 5.1)5.1 (1.9 to 10.8)
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · Stratified Fine and Gray Test · p = 0.02
Secondary12 Month Cumulative Incidence of Salvage Neurosurgical Resection

Clinical assessment of first use of neurosurgical resection as salvage therapy. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.

Time frame:
Through study completion, an average of 1 year
Reported as:
Number · percent of participants
12 Month Cumulative Incidence of Salvage Neurosurgical Resection
percent of participantsHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
12 Month Cumulative Incidence of Salvage Neurosurgical Resection6.3 (2.6 to 12.5)9.4 (4.6 to 16.3)
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · Stratified Fine and Gray Test · p = 0.41
SecondaryMean Barthel Index Score at Baseline

Barthel Index ranges from 0 to 100 with higher scores indicating greater functional independence. A greater difference between the groups indicates greater functional independence in the stereotactic arm. Here we report the mean Barthel Index score at baseline for both arms.

Time frame:
Baseline
Reported as:
Mean · score on a scale
Mean Barthel Index Score at Baseline
score on a scaleHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
Mean Barthel Index Score at Baseline92.2 ± 12.693.9 ± 10.9
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · Mean difference (net): 1.53 · 95% CI -1.95 to 5.01Mean differences should be interpreted as the stereotactic radiation group minus the hippocampal-avoidance whole brain radiation group; positive differences reflect higher functional independence (Barthel Index) of the stereotactic radiation group.
SecondaryChange in Barthel Index Score at 4-months and 12-months Post-baseline

Barthel Index ranges from 0 to 100 with higher scores indicating greater functional independence. A greater difference between the groups indicates greater functional independence in the stereotactic arm. Here we report the mean difference (95% Confidence Interval) at each timepoint.

Time frame:
4 Months and 12 months
Reported as:
Mean · score on a scale
Change in Barthel Index Score at 4-months and 12-months Post-baseline
score on a scaleHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
4 Months-2.1 ± 13.91.8 ± 10.5
12 Months-4.9 ± 15.60.3 ± 4.9
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · t-test, 2 sided · p = 0.02 · Mean difference (net): 6.79 · 95% CI 1.19 to 12.38Mean differences should be interpreted as the stereotactic radiation group minus the hippocampal-avoidance whole brain radiation group; positive differences reflect higher functional independence (Barthel Index) of the stereotactic radiation group.
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · t-test, 2 sided · p = 0.02 · Mean difference (net): 7.92 · 95% CI 1.34 to 14.49Mean differences should be interpreted as the stereotactic radiation group minus the hippocampal-avoidance whole brain radiation group; positive differences reflect higher functional independence (Barthel Index) of the stereotactic radiation group.
SecondaryKarnofsky Performance Status

The Karnofsky Performance Status (KPS) is a tool designed to assess a cancer patient's functional status. Scores range from 0 to 100 with higher scores indicating better function. Scores 90-100 indicate that the patient is independent and can perform daily activities with little to no effort. A score of 80 indicates that the patient can conduct their normal activities with some effort. A score of 70 indicates that a patient can care for themself but cannot carry on normal activities independently. Here we report the least squares mean Karnofsky Performance Score for each arm based on the Karnofsky Performance Status Scale at each timepoint from Baseline to 12 Months post-baseline.

Time frame:
Baseline to 12 Months
Reported as:
Least squares mean · score on a scale
Karnofsky Performance Status
score on a scaleHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
Baseline84.67 ± 0.7483.80 ± 0.73
3 Weeks80.96 ± 1.1983.85 ± 0.94
2 Months77.58 ± 1.6884.10 ± 0.93
4 Months75.38 ± 2.0384.89 ± 0.94
6 Months75.86 ± 2.0383.37 ± 1.22
8 Months73.89 ± 2.1085.69 ± 0.96
10 Months77.85 ± 1.8485.62 ± 1.12
12 Months77.27 ± 1.7285.91 ± 1.11
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · Mean difference (net): -0.87 · 95% CI -2.91 to 1.18
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · t-test, 2 sided · p = 0.06 · Mean difference (net): 2.89 · 95% CI -0.09 to 5.87Mean difference between arms should be interpreted as the SRS arm minus the HA-WBRT arm. Larger positive differences indicate better performance in the stereotactic arm
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · t-test, 2 sided · p = 0.001 · Mean difference (net): 6.53 · 95% CI 2.77 to 10.28Mean difference between arms should be interpreted as the SRS arm minus the HA-WBRT arm. Larger positive differences indicate better performance in the stereotactic arm
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · t-test, 2 sided · p = <0.001 · Mean difference (net): 9.51 · 95% CI 5.12 to 13.90Mean difference between arms should be interpreted as the SRS arm minus the HA-WBRT arm. Larger positive differences indicate better performance in the stereotactic arm
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · t-test, 2 sided · p = 0.002 · Mean difference (net): 7.51 · 95% CI 2.87 to 12.14Mean difference between arms should be interpreted as the SRS arm minus the HA-WBRT arm. Larger positive differences indicate better performance in the stereotactic arm
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · t-test, 2 sided · p = <0.001 · Mean difference (net): 11.80 · 95% CI 7.29 to 16.32Mean difference between arms should be interpreted as the SRS arm minus the HA-WBRT arm. Larger positive differences indicate better performance in the stereotactic arm
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · t-test, 2 sided · p = <0.001 · Mean difference (net): 7.86 · 95% CI 3.55 to 11.98Mean difference between arms should be interpreted as the SRS arm minus the HA-WBRT arm. Larger positive differences indicate better performance in the stereotactic arm
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · t-test, 2 sided · p = <0.001 · Mean difference (net): 8.64 · 95% CI 4.62 to 12.66Mean difference between arms should be interpreted as the SRS arm minus the HA-WBRT arm. Larger positive differences indicate better performance in the stereotactic arm
SecondaryHopkins Verbal Learning Test-Revised Total Recall Z-Score at Baseline

Here we report the mean Hopkins Verbal Learning Test-Revised Total Recall (HVLT-R Total Recall) z-score in each arm at baseline. The HVLT-R Total Recall test measures rote verbal learning across 3 trials administered in one sitting. Scores were transformed into z scores. Z scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The Z-Score central value is 0 and represents the population mean. Larger positive z scores indicate better neurocognitive function.

Time frame:
Baseline
Reported as:
Mean · z score
Hopkins Verbal Learning Test-Revised Total Recall Z-Score at Baseline
z scoreHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
Hopkins Verbal Learning Test-Revised Total Recall Z-Score at Baseline-1.01 ± 1.30-0.99 ± 1.42
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · Mean difference (net): 0.02 · 95% CI -0.39 to 0.44
SecondaryChange in Hopkins Verbal Learning Test-Revised Total Recall Mean Z-Score at 4-Months and 12-Months Post-baseline

Here we report the mean Hopkins Verbal Learning Test-Revised Total Recall (HVLT-R Total Recall) z-score in each arm at the given timepoint. The HVLT-R Total Recall test measures rote verbal learning across 3 trials administered in one sitting. Scores were transformed into z scores. Z scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The Z-Score central value is 0 and represents the population mean. Larger positive z scores indicate better neurocognitive function.

Time frame:
4 Months and 12 Months
Reported as:
Mean · z score
Change in Hopkins Verbal Learning Test-Revised Total Recall Mean Z-Score at 4-Months and 12-Months Post-baseline
z scoreHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
4 Months-0.04 ± 1.410.40 ± 1.28
12 Months-0.53 ± 1.580.11 ± 1.22
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · t-test, 2 sided · p = 0.20 · Mean difference (net): 0.37 · 95% CI -0.19 to 0.93Mean differences should be interpreted as the stereotactic radiation group minus the hippocampal-avoidance whole brain radiation group; positive differences reflect better performance the stereotactic radiation group.
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · t-test, 2 sided · p = 0.03 · Mean difference (net): 0.83 · 95% CI 0.07 to 1.59Mean differences should be interpreted as the stereotactic radiation group minus the hippocampal-avoidance whole brain radiation group; positive differences reflect better performance the stereotactic radiation group.
SecondaryHopkins Verbal Learning Test-Revised Delayed Recall Z-Score at Baseline

Here we report the mean Hopkins Verbal Learning Test-Revised Delayed Recall Z score at baseline. This test measures delayed memory function. Scores were transformed into z scores. Z scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The Z score central value is 0 and represents the population mean. Larger positive z scores indicate better neurocognitive function.

Time frame:
Baseline
Reported as:
Mean · z score
Hopkins Verbal Learning Test-Revised Delayed Recall Z-Score at Baseline
z scoreHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
Hopkins Verbal Learning Test-Revised Delayed Recall Z-Score at Baseline-1.01 ± 1.30-0.99 ± 1.42
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · Mean difference (net): -0.06 · 95% CI -0.54 to 0.42
SecondaryChange in Hopkins Verbal Learning Test-Revised Delayed Recall Z Scores at 4 Months and 12 Months

Here we report the mean Hopkins Verbal Learning Test-Revised Delayed Recall Z score at the given timepoint. This test measures delayed memory function. Scores were transformed into z scores. Z scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The Z score central value is 0 and represents the population mean. Larger positive z scores indicate better neurocognitive function.

Time frame:
4 Months and 12 months post-baseline
Reported as:
Mean · z score
Change in Hopkins Verbal Learning Test-Revised Delayed Recall Z Scores at 4 Months and 12 Months
z scoreHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
4 Months-0.04 ± 1.410.40 ± 1.28
12 Months-0.53 ± 1.580.11 ± 1.22
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · t-test, 2 sided · p = 0.19 · Mean difference (net): 0.43 · 95% CI -0.21 to 1.07Mean differences should be interpreted as the stereotactic radiation group minus the hippocampal-avoidance whole brain radiation group; positive differences reflect better performance the stereotactic radiation group.
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · t-test, 2 sided · p = 0.03 · Mean difference (net): 0.83 · 95% CI 0.07 to 1.59Mean differences should be interpreted as the stereotactic radiation group minus the hippocampal-avoidance whole brain radiation group; positive differences reflect better performance the stereotactic radiation group.
SecondaryHopkins Verbal Learning Test-Revised Recognition Z Score at Baseline

Here we report the mean Hopkins Verbal Learning Test-Revised Recognition z scores in each arm at baseline. The Hopkins Verbal Learning Test - Revised Recognition measures memory storage and recognition. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the populaion mean. Larger, positive z scores indicate better neurocognitive function. Here we report the mean z score in each arm at baseline.

Time frame:
Baseline
Reported as:
Mean · z score
Hopkins Verbal Learning Test-Revised Recognition Z Score at Baseline
z scoreHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
Hopkins Verbal Learning Test-Revised Recognition Z Score at Baseline-0.49 ± 1.28-0.51 ± 1.65
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · Mean difference (net): -0.03 · 95% CI -0.49 to 0.43Mean differences should be interpreted as the stereotactic radiation group minus the hippocampal-avoidance whole brain radiation group; positive differences reflect better performance the stereotactic radiation group.
SecondaryChange in Hopkins Verbal Learning Test-Revised Recognition Z-score at 4 Months and 12 Months

Here we report the mean Hopkins Verbal Learning Test-Revised Recognition z scores in each arm at the given timepoint. The Hopkins Verbal Learning Test - Revised Recognition measures memory storage and recognition. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the populaion mean. Larger, positive z scores indicate better neurocognitive function. Here we report the mean z score in each arm at the given timepoint.

Time frame:
4 Months and 12 Months post baseline
Reported as:
Mean · z score
Change in Hopkins Verbal Learning Test-Revised Recognition Z-score at 4 Months and 12 Months
z scoreHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
4 Months0.03 ± 1.830.12 ± 1.13
12 Months-1.12 ± 2.480.05 ± 0.88
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · t-test, 2 sided · p = 0.43 · Mean difference (net): 0.24 · 95% CI -0.35 to 0.82Mean differences should be interpreted as the stereotactic radiation group minus the hippocampal-avoidance whole brain radiation group; positive differences reflect better performance the stereotactic radiation group.
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · t-test, 2 sided · p = 0.004 · Mean difference (net): 1.62 · 95% CI 0.52 to 2.72Mean differences should be interpreted as the stereotactic radiation group minus the hippocampal-avoidance whole brain radiation group; positive differences reflect better performance the stereotactic radiation group.
SecondaryTrail Making Test A, Z Score at Baseline

Here we report the mean Trail Making Test A z score in each arm at baseline. The Trail Making Test A measures visuomotor processing speed. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the population mean. Larger, positive z scores inicate better visuomotor processing speed.

Time frame:
Baseline
Reported as:
Mean · z score
Trail Making Test A, Z Score at Baseline
z scoreHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
Trail Making Test A, Z Score at Baseline-1.41 ± 4.52-0.86 ± 2.81
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · Mean difference (net): 0.55 · 95% CI -0.63 to 1.73Mean differences should be interpreted as the stereotactic radiation group minus the hippocampal-avoidance whole brain radiation group; positive differences reflect better performance the stereotactic radiation group.
SecondaryChange in Trail Making Test A Z-Score From Baseline at 4 Months and 12 Months

Here we report the mean Trail Making Test A z score in each arm at the given timepoint. The Trail Making Test A measures visuomotor processing speed. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the population mean. Larger, positive z scores inicate better visuomotor processing speed.

Time frame:
at 4 Months and 12 Months
Reported as:
Mean · z score
Change in Trail Making Test A Z-Score From Baseline at 4 Months and 12 Months
z scoreHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
4 Months-0.15 ± 1.750.54 ± 2.30
12 Months-2.17 ± 6.32-0.24 ± 0.89
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · t-test, 2 sided · p = 0.02 · Mean difference (net): 0.86 · 95% CI 0.11 to 1.60Mean differences should be interpreted as the stereotactic radiation group minus the hippocampal-avoidance whole brain radiation group; positive differences reflect better performance the stereotactic radiation group.
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · t-test, 2 sided · p = 0.06 · Mean difference (net): 2.95 · 95% CI -0.10 to 5.99Mean differences should be interpreted as the stereotactic radiation group minus the hippocampal-avoidance whole brain radiation group; positive differences reflect better performance the stereotactic radiation group.
SecondaryTrail Making Test B Z Score at Baseline

Here we report the mean Trail Making Test B z score in each arm at baseline. The Trail Making Test B measures visuomotor processing speed. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the population mean. Larger, positive z scores inicate better visuomotor processing speed.

Time frame:
Baseline
Reported as:
Mean · z score
Trail Making Test B Z Score at Baseline
z scoreHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
Trail Making Test B Z Score at Baseline-3.40 ± 12.1-3.50 ± 6.91
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · Mean difference (net): -0.13 · 95% CI -3.26 to 3.01
SecondaryTrail Making Test B Z Score at 4 Months and 12 Months Post-baseline

Here we report the mean Trail Making Test B z score in each arm at the given timepoint. The Trail Making Test B measures visuomotor processing speed. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the population mean. Larger, positive z scores inicate better visuomotor processing speed.

Time frame:
4 Months and 12 months post-baseline
Reported as:
Mean · z score
Trail Making Test B Z Score at 4 Months and 12 Months Post-baseline
z scoreHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
4 Months-0.83 ± 2.650.92 ± 3.88
12 Months-3.53 ± 8.101.49 ± 5.81
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · t-test, 2 sided · p = 0.35 · Mean difference (net): 0.78 · 95% CI -0.84 to 2.40Mean differences should be interpreted as the stereotactic radiation group minus the hippocampal-avoidance whole brain radiation group; positive differences reflect better performance the stereotactic radiation group.
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · t-test, 2 sided · p = 0.03 · Mean difference (net): 4.11 · 95% CI 0.37 to 7.86Mean differences should be interpreted as the stereotactic radiation group minus the hippocampal-avoidance whole brain radiation group; positive differences reflect better performance the stereotactic radiation group.
SecondaryControlled Oral Word Test Z Score at Baseline

Here we report the mean controlled oral word test z score in each arm at baseline. The controlled oral word test (COWAT) measures verbal fluency. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the population mean. A larger positive z score indicates better performance.

Time frame:
Baseline
Reported as:
Mean · z score
Controlled Oral Word Test Z Score at Baseline
z scoreHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
Controlled Oral Word Test Z Score at Baseline-0.62 ± 1.20-0.72 ± 1.07
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · Mean difference (net): -0.07 · 95% CI -0.43 to 0.28Mean differences should be interpreted as the stereotactic radiation group minus the hippocampal-avoidance whole brain radiation group; positive differences reflect better performance the stereotactic radiation group.
SecondaryChange in Controlled Oral Word Test Z Score at 4 Months and 12 Months Post Baseline

Here we report the change in mean controlled oral word test z score in each arm at the given timepoints from baseline. The controlled oral word test (COWAT) measures verbal fluency. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the population mean. A larger positive z score indicates better performance.

Time frame:
4 Months and 12 months post baseline
Reported as:
Mean · z score
Change in Controlled Oral Word Test Z Score at 4 Months and 12 Months Post Baseline
z scoreHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
4 Months-0.39 ± 0.760.20 ± 0.80
12 Months-0.18 ± 0.940.27 ± 0.72
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · t-test, 2 sided · p = 0.007 · Mean difference (net): 0.53 · 95% CI 0.14 to 0.91Mean differences should be interpreted as the stereotactic radiation group minus the hippocampal-avoidance whole brain radiation group; positive differences reflect better performance the stereotactic radiation group.
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · t-test, 2 sided · p = 0.08 · Mean difference (net): 0.47 · 95% CI -0.05 to 0.98Mean differences should be interpreted as the stereotactic radiation group minus the hippocampal-avoidance whole brain radiation group; positive differences reflect better performance the stereotactic radiation group.
SecondaryMini-Mental State Examination Mean at Baseline

Here we report the Mini-Mental State Examination mean in each arm at baseline. The Mini-Mental State Examination measures global cognition on a scale from 0 to 30. Higher scores indicate better perfromance.

Time frame:
Baseline
Reported as:
Mean · score on a scale
Mini-Mental State Examination Mean at Baseline
score on a scaleHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
Mini-Mental State Examination Mean at Baseline27.6 ± 2.4927.6 ± 2.54
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · Mean difference (net): 0 · 95% CI -0.79 to 0.79Mean differences should be interpreted as the stereotactic radiation group minus the hippocampal-avoidance whole brain radiation group; positive differences reflect better performance the stereotactic radiation group.
SecondaryChange in Mini-Mental State Examination Score at 4 Months and 12 Months Post Baseline

Here we report the change in the mean Mini-Mental State Examination z score in each arm at the given timepoints. The Mini-Mental State Examination Scores measures global cognition on a scale from 0 to 30. Test scores were transformed into z scores Larger positive scores indicate better performance. Z scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The Z-Score central value is 0 and represents the population mean. Larger, positive differences indicate better global cognition.

Time frame:
4 Months and 12 months post baseline
Reported as:
Mean · z score
Change in Mini-Mental State Examination Score at 4 Months and 12 Months Post Baseline
z scoreHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
4 Months-0.11 ± 2.480.39 ± 2.26
12 Months-0.80 ± 2.210.44 ± 2.75
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · t-test, 2 sided · p = 0.53 · Mean difference (net): 0.53 · 95% CI -0.53 to 1.59Mean differences should be interpreted as the stereotactic radiation group minus the hippocampal-avoidance whole brain radiation group; positive differences reflect better performance the stereotactic radiation group.
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · t-test, 2 sided · p = 0.21 · Mean difference (net): 0.86 · 95% CI -0.49 to 2.21Mean differences should be interpreted as the stereotactic radiation group minus the hippocampal-avoidance whole brain radiation group; positive differences reflect better performance the stereotactic radiation group.
SecondaryMedical Outcomes Study Cognitive Functioning Scale-Revised Normative Score at Baseline

Scores global cognition on a scale from 0 to 100. Higher scores indicate better cognitive function. Scores were transformed into normative scores ranging from 7.51 to 58.61. Larger scores indicate better function.

Time frame:
Baseline
Reported as:
Mean · score on a scale
Medical Outcomes Study Cognitive Functioning Scale-Revised Normative Score at Baseline
score on a scaleHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
Medical Outcomes Study Cognitive Functioning Scale-Revised Normative Score at Baseline50.5 ± 10.149.0 ± 10.3
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · Mean difference (net): -1.50 · 95% CI -4.49 to 1.49Mean differences should be interpreted as the stereotactic radiation group minus the hippocampal-avoidance whole brain radiation group; positive differences reflect better performance the stereotactic radiation group.
SecondaryChange in Medical Outcomes Study Cognitive Functioning Scale-Revised Normative Scores at 4 Months and 12 Months Post Baseline

Scores global cognition on a scale from 0 to 100. Higher scores indicate better cognitive function. Scores were transformed into normative scores ranging from 7.51 to 58.61. Larger positive differences indicate better function.

Time frame:
4 Months and 12 months post baseline
Reported as:
Mean · score on a scale
Change in Medical Outcomes Study Cognitive Functioning Scale-Revised Normative Scores at 4 Months and 12 Months Post Baseline
score on a scaleHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
4 Months-0.38 ± 8.453.01 ± 9.49
12 Months-2.69 ± 9.14-0.83 ± 9.60
Statistical analysis
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · t-test, 2 sided · p = 0.36 · Mean difference (net): 1.39 · 95% CI -1.58 to 4.39Mean differences should be interpreted as the stereotactic radiation group minus the hippocampal-avoidance whole brain radiation group; positive differences reflect better performance the stereotactic radiation group.
  • Hippocampal-Avoidance Whole Brain Radiation vs Stereotactic Radiation · t-test, 2 sided · p = 0.76 · Mean difference (net): 0.76 · 95% CI -4.18 to 5.70Mean differences should be interpreted as the stereotactic radiation group minus the hippocampal-avoidance whole brain radiation group; positive differences reflect better performance the stereotactic radiation group.

Adverse events

Collected over From enrollment until participant died, withdrew, or was lost to follow up, approximately 24 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Hippocampal-Avoidance Whole Brain Radiation85/98 (86.7%)25/98 (25.5%)90/98 (91.8%)
Stereotactic Radiation80/98 (81.6%)21/98 (21.4%)89/98 (90.8%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
Death NOSGeneral disorders12/984/98
DyspneaRespiratory, thoracic and mediastinal disorders4/986/98
NauseaGastrointestinal disorders3/982/98
FatigueGeneral disorders3/981/98
HeadacheNervous system disorders0/983/98
MyelitisNervous system disorders2/980/98
HypoxiaRespiratory, thoracic and mediastinal disorders0/982/98
Febrile neutropeniaBlood and lymphatic system disorders1/980/98
Myocardial infarctionCardiac disorders1/980/98
Abdominal painGastrointestinal disorders1/980/98
Most frequent other events
Showing 10 of 141
Most frequent other events
EventHippocampal-Avoidance Whole Brain RadiationStereotactic Radiation
FatigueGeneral disorders44/9835/98
NauseaGastrointestinal disorders18/9825/98
AnorexiaMetabolism and nutrition disorders24/9812/98
HeadacheNervous system disorders20/9815/98
Blurred visionEye disorders11/9813/98
Back painMusculoskeletal and connective tissue disorders4/9813/98
SeizureNervous system disorders11/9813/98
Gait disturbanceGeneral disorders3/9812/98
Central nervous system necrosisNervous system disorders2/9811/98
DyspneaRespiratory, thoracic and mediastinal disorders7/9811/98

Baseline characteristics

Age, Customized
Age, Customized(Years)Hippocampal-Avoidance Whole Brain RadiationStereotactic RadiationTotal
Age60 ± 1361 ± 1160.8 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)Hippocampal-Avoidance Whole Brain RadiationStereotactic RadiationTotal
Female6465129
Male343367
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Hippocampal-Avoidance Whole Brain RadiationStereotactic RadiationTotal
Race — Asian268
Race — Black or African American246
Race — White9086176
Race — More than 1 race303
Race — Other123
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Hippocampal-Avoidance Whole Brain RadiationStereotactic RadiationTotal
Hispanic or Latino Ethnicity617
Non-Hispanic8793180
Unknown549
Charlson Comorbidity Index
Charlson Comorbidity Index(score on a scale)Hippocampal-Avoidance Whole Brain RadiationStereotactic RadiationTotal
Median0 (0 to 1)0 (0 to 1)0 (0 to 1)
Karnofsky Performance Status
Karnofsky Performance Status(Participants)Hippocampal-Avoidance Whole Brain RadiationStereotactic RadiationTotal
100426
90414586
80393877
7081220
Unknown617
Primary Cancer
Primary Cancer(Participants)Hippocampal-Avoidance Whole Brain RadiationStereotactic RadiationTotal
Non-small cell lung cancer434487
Breast232144
Melanoma9918
Other232447
Neurologic Symptoms
Neurologic Symptoms(Participants)Hippocampal-Avoidance Whole Brain RadiationStereotactic RadiationTotal
Count of participants6060120

8 further baseline measures are reported on the registry.

08

Study locations

2 sites
09

References and documents

Publications

  • Ayal Aizer et al. Stereotactic radiation versus hippocampal avoidance whole brain radiation in patients with 5-20 brain metastases: A multicenter, phase 3 randomized trial.. J Clin Oncol 43, 2011-2011(2025). DOI:10.1200/JCO.2025.43.16_suppl.2011
  • Aizer A et al. Multicenter, Phase 3 Randomized Trial of Stereotactic Radiation vs. Hippocampal Avoidance Whole Brain Radiation in Patients with 5-20 Brain Metastases: Recurrence, Salvage Therapy, and Mortality Endpoints International Journal of Radiation Oncology, Biology, Physics, 123, S33-S34
  • Michael Parsons, Kee-Young Shin, Jennifer Nosker, Shyam Tanguturi, Paul Catalano, Daphne Haas-Kogan, Jaroslaw Hepel, Marciana Johnson, Grant Benham, Ivy Ricca, Rifaquatn Rahma, Ayal Aizer, NCOG-20. Stereotactic radiation versus hippocampal avoidant whole brain radiation in patients with 5-20 brain metastases: Cognitive outcomes of 12-month survivors, Neuro-Oncology, Volume 27, Issue Supplement_5, November 2025, Pages v325-v326, https://doi.org/10.1093/neuonc/noaf201.1287
  • Aizer AA, Shin KY, Catalano PJ, Ricca I, Johnson M, Benham G, Roper K, Spicer B, Mann E, Nosker J, Parsons MW, Mendu ML, Hepel J, Chipidza F, Krishnan M, Shi DD, Lamba N, Pashtan I, Peng L, Alexander B, Brown PD, Wen PY, Haas-Kogan DA, Rahman R, Tanguturi S. Treatment for Brain Metastases With Stereotactic Radiation vs Hippocampal-Avoidance Whole Brain Radiation: A Randomized Clinical Trial. JAMA. 2026 Apr 7;335(13):1127-1136. doi: 10.1001/jama.2026.0076. PubMed 41712219 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Nov 2024, 90 months.

Results were first posted in Sep 2026, 1 year 10 months after primary completion.

Of 310 non-industry interventional studies with no phase under Brain Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's 90 months is above that.

Counting every sponsor, half of 321 studies reached it within 64 months; a quarter within 35 and three quarters within 125.

Completion moved once since we started tracking on Sep 25, 2026: Sep 2025 → Sep 2027, on Sep 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2017
First posted
Mar 9, 2017
StartActual
Apr 10, 2017
Primary completionActual
Nov 7, 2024
CompletionEst.
Sep 30, 2027was Sep 2025
Results first posted
Sep 29, 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 29, 2026
Study completion
Sep 30, 2025→Sep 30, 2027
Sep 29, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Quality of Life Survey (symptoms and interference)Now Change in MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT) ScoreTime frame: 6 months → Baseline and 6 months post-Baseline
Sep 29, 2026
Documents
Publications
Results publication added: Aizer AA, Shin KY, Catalano PJ, Ricca I, Johnson M, Benham G, Roper K, Spicer B, Mann E, Nosker J, Parsons MW, Mendu ML, Hepel J, Chipidza F, Krishnan M, Shi D… PubMed 41712219 ↗; 3 more
Sep 29, 2026
Secondary outcomes
7 edited, 23 added, 5 more
What changed in the outcomes
  • EditedOverall survivalSurvivalTime frame: Through study completion, an average of 1 year
  • Edited12 Month Cumulative Incidence and time to detection of new brain metastasesNew Brain MetastasesTime frame: Through study completion, an average of 1 year
  • Edited12 Month Cumulative Incidence and time to local recurrence of treated brain tumorLocal Recurrence of Treated Brain Tumor(s)Time frame: Through study completion, an average of 1 year
  • Edited12 Month Cumulative Incidence and time to development of radiation necrosisRadiographic Radiation NecrosisTime frame: Through study completion, an average of 1 year
  • Edited12 Month Cumulative Incidence and time to development of leptomeningeal diseaseLeptomeningeal DiseaseTime frame: Through study completion, an average of 1 year
  • Edited12 Month Cumulative Incidence and time to the development of seizuresDevelopment of SeizuresTime frame: Through study completion, an average of 1 year
  • EditedKarnofsky Performance statusStatusTime frame: Through study completion, an average of 1 year → Baseline to 12 Months
  • Added12 Month Cumulative Incidence of Neurologic DeathTime frame: Through study completion, an average of 1 year
  • Added12 Month Cumulative Incidence of Progressive Intracranial DiseaseTime frame: Through study completion, an average of 1 year
  • Added12 Month Cumulative Incidence of Dexamethasone InitiationTime frame: Through study completion, an average of 1 year
  • Added12 Month Cumulative Incidence of Salvage Stereotactic RadiationTime frame: Through study completion, an average of 1 year
  • Added12 Month Cumulative Incidence of Salvage Whole Brain RadiationTime frame: Through study completion, an average of 1 year
  • Added12 Month Cumulative Incidence of Salvage Neurosurgical ResectionTime frame: Through study completion, an average of 1 year
  • AddedMean Barthel Index Score at BaselineTime frame: Baseline
  • AddedChange in Barthel Index Score at 4-months and 12-months Post-baselineTime frame: 4 Months and 12 months
  • AddedHopkins Verbal Learning Test-Revised Total Recall Z-Score at BaselineTime frame: Baseline
  • AddedChange in Hopkins Verbal Learning Test-Revised Total Recall Mean Z-Score at 4-Months and 12-Months Post-baselineTime frame: 4 Months and 12 Months
  • AddedHopkins Verbal Learning Test-Revised Delayed Recall Z-Score at BaselineTime frame: Baseline
  • AddedChange in Hopkins Verbal Learning Test-Revised Delayed Recall Z Scores at 4 Months and 12 MonthsTime frame: 4 Months and 12 months post-baseline
  • AddedHopkins Verbal Learning Test-Revised Recognition Z Score at BaselineTime frame: Baseline
  • AddedChange in Hopkins Verbal Learning Test-Revised Recognition Z-score at 4 Months and 12 MonthsTime frame: 4 Months and 12 Months post baseline
  • AddedTrail Making Test A, Z Score at BaselineTime frame: Baseline
  • AddedChange in Trail Making Test A Z-Score From Baseline at 4 Months and 12 MonthsTime frame: at 4 Months and 12 Months
  • AddedTrail Making Test B Z Score at BaselineTime frame: Baseline
  • AddedTrail Making Test B Z Score at 4 Months and 12 Months Post-baselineTime frame: 4 Months and 12 months post-baseline
  • AddedControlled Oral Word Test Z Score at BaselineTime frame: Baseline
  • AddedChange in Controlled Oral Word Test Z Score at 4 Months and 12 Months Post BaselineTime frame: 4 Months and 12 months post baseline
  • AddedMini-Mental State Examination Mean at BaselineTime frame: Baseline
  • AddedChange in Mini-Mental State Examination Score at 4 Months and 12 Months Post BaselineTime frame: 4 Months and 12 months post baseline
  • AddedMedical Outcomes Study Cognitive Functioning Scale-Revised Normative Score at BaselineTime frame: Baseline
  • …and 5 more, on the record history on ClinicalTrials.gov ↗
Sep 29, 2026
Sponsor
Dana-Farber Cancer Institute→Brigham and Women's Hospital; Collaborators added: Dana-Farber Cancer Institute; collaborators removed: Brigham and Women's Hospital
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Results posted
    Publications Results publication added: Aizer AA, Shin KY, Catalano PJ, Ricca I, Johnson M, Benham G, Roper K, Spicer B, Mann E, Nosker J, Parsons MW, Mendu ML, Hepel J, Chipidza F, Krishnan M, Shi D… PubMed 41712219 ↗; 3 more
    Study completion Sep 30, 2025→Sep 30, 2027
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Quality of Life Survey (symptoms and interference)Now Change in MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT) ScoreTime frame: 6 months → Baseline and 6 months post-Baseline
    Secondary outcomes 7 edited, 23 added, 5 more
    What changed in the outcomes
    • EditedOverall survivalSurvivalTime frame: Through study completion, an average of 1 year
    • Edited12 Month Cumulative Incidence and time to detection of new brain metastasesNew Brain MetastasesTime frame: Through study completion, an average of 1 year
    • Edited12 Month Cumulative Incidence and time to local recurrence of treated brain tumorLocal Recurrence of Treated Brain Tumor(s)Time frame: Through study completion, an average of 1 year
    • Edited12 Month Cumulative Incidence and time to development of radiation necrosisRadiographic Radiation NecrosisTime frame: Through study completion, an average of 1 year
    • Edited12 Month Cumulative Incidence and time to development of leptomeningeal diseaseLeptomeningeal DiseaseTime frame: Through study completion, an average of 1 year
    • Edited12 Month Cumulative Incidence and time to the development of seizuresDevelopment of SeizuresTime frame: Through study completion, an average of 1 year
    • EditedKarnofsky Performance statusStatusTime frame: Through study completion, an average of 1 year → Baseline to 12 Months
    • Added12 Month Cumulative Incidence of Neurologic DeathTime frame: Through study completion, an average of 1 year
    • Added12 Month Cumulative Incidence of Progressive Intracranial DiseaseTime frame: Through study completion, an average of 1 year
    • Added12 Month Cumulative Incidence of Dexamethasone InitiationTime frame: Through study completion, an average of 1 year
    • Added12 Month Cumulative Incidence of Salvage Stereotactic RadiationTime frame: Through study completion, an average of 1 year
    • Added12 Month Cumulative Incidence of Salvage Whole Brain RadiationTime frame: Through study completion, an average of 1 year
    • Added12 Month Cumulative Incidence of Salvage Neurosurgical ResectionTime frame: Through study completion, an average of 1 year
    • AddedMean Barthel Index Score at BaselineTime frame: Baseline
    • AddedChange in Barthel Index Score at 4-months and 12-months Post-baselineTime frame: 4 Months and 12 months
    • AddedHopkins Verbal Learning Test-Revised Total Recall Z-Score at BaselineTime frame: Baseline
    • AddedChange in Hopkins Verbal Learning Test-Revised Total Recall Mean Z-Score at 4-Months and 12-Months Post-baselineTime frame: 4 Months and 12 Months
    • AddedHopkins Verbal Learning Test-Revised Delayed Recall Z-Score at BaselineTime frame: Baseline
    • AddedChange in Hopkins Verbal Learning Test-Revised Delayed Recall Z Scores at 4 Months and 12 MonthsTime frame: 4 Months and 12 months post-baseline
    • AddedHopkins Verbal Learning Test-Revised Recognition Z Score at BaselineTime frame: Baseline
    • AddedChange in Hopkins Verbal Learning Test-Revised Recognition Z-score at 4 Months and 12 MonthsTime frame: 4 Months and 12 Months post baseline
    • AddedTrail Making Test A, Z Score at BaselineTime frame: Baseline
    • AddedChange in Trail Making Test A Z-Score From Baseline at 4 Months and 12 MonthsTime frame: at 4 Months and 12 Months
    • AddedTrail Making Test B Z Score at BaselineTime frame: Baseline
    • AddedTrail Making Test B Z Score at 4 Months and 12 Months Post-baselineTime frame: 4 Months and 12 months post-baseline
    • AddedControlled Oral Word Test Z Score at BaselineTime frame: Baseline
    • AddedChange in Controlled Oral Word Test Z Score at 4 Months and 12 Months Post BaselineTime frame: 4 Months and 12 months post baseline
    • AddedMini-Mental State Examination Mean at BaselineTime frame: Baseline
    • AddedChange in Mini-Mental State Examination Score at 4 Months and 12 Months Post BaselineTime frame: 4 Months and 12 months post baseline
    • AddedMedical Outcomes Study Cognitive Functioning Scale-Revised Normative Score at BaselineTime frame: Baseline
    • …and 5 more, on the record history on ClinicalTrials.gov ↗
    Sponsor Dana-Farber Cancer Institute→Brigham and Women's Hospital; Collaborators added: Dana-Farber Cancer Institute; collaborators removed: Brigham and Women's Hospital
    + 4 other changes: identifiers, verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03075072
Responsible party
Ayal A. Aizer, MD (Principal Investigator, Brigham and Women's Hospital) — Principal investigator
First posted
Mar 9, 2017
Start date
Apr 10, 2017
Primary completion
Nov 7, 2024
Completion
Sep 30, 2027 (estimated)
Results posted
Sep 29, 2026
Last update
Sep 29, 2026

Study contacts

Ayal Aizer, MD MHS
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion